Real-world Evidence (RWE) Solutions Market: Components and Applications

 

Meticulous Research®—leading global market research company published a research report titled “Real-world Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Global Forecast to 2029.”

 

Download Free Sample Report @ https://www.meticulousresearch.com/download-sample-report/cp_id=4954?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=07-05-2024

 

According to this latest publication from Meticulous Research®, the real-world evidence (RWE) solutions market is expected to grow at a CAGR of 11.8% from 2022–2029 to reach $4.9 billion by 2029. The rapid growth of large data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are expected to positively impact the RWE solutions market. However, the lack of standardized methodologies to develop RWE is a major challenge for the growth of this market.

 

The RWE solutions market study presents historical market data in terms of values (2020 and 2021), estimated current data (2022), and forecasts for 2029. The market is segmented by Component (Datasets and Consulting Services), Application (Market Access & Reimbursement/Coverage Decisions, Drug Development & Approvals, Post Market Surveillance, Medical Device Development & Approvals, and Other Applications), End User (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, and Other End Users), and Geography. The study also evaluates industry competitors and analyzes their market shares at the global and regional levels.

 

Browse in depth @ https://www.meticulousresearch.com/product/real-world-evidence-solutions-market-4954?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=07-05-2024

 

Based on component, the datasets segment is estimated to account for a larger share of the RWE solutions market in 2022. The large share of this segment is mainly attributed to the growing amount of medical data generated in hospitals and the increasing dependence of outcome-based studies on real-world data. EHRs are the most commonly used form of healthcare database that helps in conducting outcome-based studies. EHR data is playing an increasingly vital role in collecting and generating actionable information at the FDA. Governments across the world are undertaking initiatives to increase the adoption of EHR/EMR data. For instance, in September 2020, to digitalize the entire healthcare ecosystem of India, the Ministry of Health and Family Welfare (MoHFW) released a draft policy termed the Health Data Management Policy.

 

Based on application, the market access & reimbursement/coverage decisions segment is estimated to account for the largest share of the RWE solutions market in 2022. The pharmaceutical, biotech, and medical device industries face unprecedented challenges due to the global economic crisis, COVID-19 pandemic, and concerns about escalating healthcare costs. Due to rising therapy costs, healthcare payers are increasingly focused on evidence of clinical value for making decisions associated with providing coverage. RWE helps provide a means for demonstrating value, ranging from confirming randomized trial benefits in real-world populations to a fuller characterization of resource impacts. Real-world data (RWD) is being increasingly considered by both industry and payers. Payers use the data to support coverage decisions, develop guidelines and decision support tools for use in clinical practice, generate estimates of the potential population they cover that could require the treatment, and estimate potential costs and cost offsets.

 

Speck to our analyst @  https://www.meticulousresearch.com/speak-to-analyst/cp_id=4954?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=07-05-2024

 

Based on end user, the pharmaceutical & medical device companies segment is estimated to account for a larger share of the RWE solutions market in 2022. The large market share of this segment is mainly attributed increasing importance of RWE studies in drug development & approvals, and the growing need to avoid costly drug recalls and assess drug performance in real-world settings. The healthcare landscape continues to shift from volume to value-based care and is continuously developing. Pharmaceutical companies have been looking for new ways to provide the best treatments for patients. Real-world evidence helps in understanding real-life clinical practices and actual health outcomes of drugs. Pharmaceutical and biotech companies are increasingly utilizing real-world evidence for collecting real-time post-trial information about drugs, which helps healthcare providers and researchers understand the negative reactions, side effects, and medication errors related to the drugs, thereby enabling them to control the potential harm caused by the drugs.

 

This research report analyzes major geographies and provides comprehensive analysis for North America (U.S., Canada), Asia-Pacific (China, Japan, India, Australia, and RoAPAC), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Latin America, and the Middle East & Africa.

 

Key companies operating in the global RWE solutions market are Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

 

TOP 10 COMPANIES IN REAL-WORLD EVIDENCE (RWE) SOLUTIONS MARKET >>  https://meticulousblog.org/top-10-companies-in-real-world-evidence-solutions-market/?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=07-05-2024

 

Related Report:

TOP 10 COMPANIES IN U.S. REAL WORLD EVIDENCE SOLUTIONS MARKET >>  https://meticulousblog.org/top-10-companies-in-u-s-real-world-evidence-solutions-market/?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=07-05-2024

Real-world Evidence (RWE) Solutions Market: Components and Applications

 

Meticulous Research®—leading global market research company published a research report titled “Real-world Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Global Forecast to 2029.”

 

Download Free Sample Report @ https://www.meticulousresearch.com/download-sample-report/cp_id=4954?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=25-04-2024

 

According to this latest publication from Meticulous Research®, the real-world evidence (RWE) solutions market is expected to grow at a CAGR of 11.8% from 2022–2029 to reach $4.9 billion by 2029. The rapid growth of large data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are expected to positively impact the RWE solutions market. However, the lack of standardized methodologies to develop RWE is a major challenge for the growth of this market.

 

The RWE solutions market study presents historical market data in terms of values (2020 and 2021), estimated current data (2022), and forecasts for 2029. The market is segmented by Component (Datasets and Consulting Services), Application (Market Access & Reimbursement/Coverage Decisions, Drug Development & Approvals, Post Market Surveillance, Medical Device Development & Approvals, and Other Applications), End User (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, and Other End Users), and Geography. The study also evaluates industry competitors and analyzes their market shares at the global and regional levels.

 

Browse in depth @ https://www.meticulousresearch.com/product/real-world-evidence-solutions-market-4954?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=25-04-2024

 

Based on component, the datasets segment is estimated to account for a larger share of the RWE solutions market in 2022. The large share of this segment is mainly attributed to the growing amount of medical data generated in hospitals and the increasing dependence of outcome-based studies on real-world data. EHRs are the most commonly used form of healthcare database that helps in conducting outcome-based studies. EHR data is playing an increasingly vital role in collecting and generating actionable information at the FDA. Governments across the world are undertaking initiatives to increase the adoption of EHR/EMR data. For instance, in September 2020, to digitalize the entire healthcare ecosystem of India, the Ministry of Health and Family Welfare (MoHFW) released a draft policy termed the Health Data Management Policy.

 

Based on application, the market access & reimbursement/coverage decisions segment is estimated to account for the largest share of the RWE solutions market in 2022. The pharmaceutical, biotech, and medical device industries face unprecedented challenges due to the global economic crisis, COVID-19 pandemic, and concerns about escalating healthcare costs. Due to rising therapy costs, healthcare payers are increasingly focused on evidence of clinical value for making decisions associated with providing coverage. RWE helps provide a means for demonstrating value, ranging from confirming randomized trial benefits in real-world populations to a fuller characterization of resource impacts. Real-world data (RWD) is being increasingly considered by both industry and payers. Payers use the data to support coverage decisions, develop guidelines and decision support tools for use in clinical practice, generate estimates of the potential population they cover that could require the treatment, and estimate potential costs and cost offsets.

 

Speck to our analyst @  https://www.meticulousresearch.com/speak-to-analyst/cp_id=4954?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=25-04-2024

 

Based on end user, the pharmaceutical & medical device companies segment is estimated to account for a larger share of the RWE solutions market in 2022. The large market share of this segment is mainly attributed increasing importance of RWE studies in drug development & approvals, and the growing need to avoid costly drug recalls and assess drug performance in real-world settings. The healthcare landscape continues to shift from volume to value-based care and is continuously developing. Pharmaceutical companies have been looking for new ways to provide the best treatments for patients. Real-world evidence helps in understanding real-life clinical practices and actual health outcomes of drugs. Pharmaceutical and biotech companies are increasingly utilizing real-world evidence for collecting real-time post-trial information about drugs, which helps healthcare providers and researchers understand the negative reactions, side effects, and medication errors related to the drugs, thereby enabling them to control the potential harm caused by the drugs.

 

This research report analyzes major geographies and provides comprehensive analysis for North America (U.S., Canada), Asia-Pacific (China, Japan, India, Australia, and RoAPAC), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Latin America, and the Middle East & Africa.

 

Key companies operating in the global RWE solutions market are Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

 

TOP 10 COMPANIES IN REAL-WORLD EVIDENCE (RWE) SOLUTIONS MARKET >>  https://meticulousblog.org/top-10-companies-in-real-world-evidence-solutions-market/?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=25-04-2024

 

Related Report:

TOP 10 COMPANIES IN U.S. REAL WORLD EVIDENCE SOLUTIONS MARKET >>  https://meticulousblog.org/top-10-companies-in-u-s-real-world-evidence-solutions-market/?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=25-04-2024

 

“Real-world Evidence (RWE) Solutions” is Transforming Healthcare

 

According to a new market research report titled, “Real-World Evidence Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Forecast to 2029”, published by Meticulous Research^®, the RWE solutions market is expected to grow at a CAGR of 11.8% from 2022–2029 to reach $4.9 billion by 2029.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=4954?utm_source=pr&utm_medium=social&utm_campaign=product&utm_content=08-12-2023

Real-world evidence (RWE) is clinical evidence gathered via RWD analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications, including drug development life cycles, shortening development timelines, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. The growth of this market is driven by key factors such as the rapid growth of large data in healthcare, the shift from volume to value-based care, and the rising focus towards personalized healthcare.

RWE Solutions Market: Outlook

The RWE solutions market is segmented by component (datasets and consulting services), application (market access & reimbursement/coverage decisions, drug development & approvals, post market surveillance, medical device development & approvals, and other applications), end user (pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users) and Geography (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa). The study also evaluates industry competitors and analyzes their market shares at the global and regional levels.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business:  https://www.meticulousresearch.com/speak-to-analyst/cp_id=4954

Based on component, the datasets segment is estimated to account for the largest share of the RWE solutions market in 2022. The large market share of this segment is attributed to the increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, increasing dependence of outcome-based studies on real-world data, and rising demand for information regarding drug safety among payers, regulatory bodies, and providers. However, the consulting services segment is expected to witness the fastest growth rate during the forecast period. Real-world evidence consulting service providers make use of robust real-world datasets generated by conducting prospective/observational studies to offer customized consulting services to generate fit-for-purpose data and insights for their stakeholders instead of providing terabytes of data.

Based on application, the market access & reimbursement/coverage decisions segment is estimated to account for the largest share of the RWE solutions market in 2022. However, the drug development & approvals segment is expected to witness the fastest growth rate during the forecast period. Factors attributing to the growth of this segment include increasing demand for real-world data and real-world evidence to accelerate drug discovery and development and increasing investments by biopharmaceutical companies in R&D. In the field of drug development, quality-of-life metrics and Patient-reported Outcome Measures (PROMs) are now becoming common elements in clinical trials. The evidence generated from real-world data is regularly utilized to inform aspects of drug development. The role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs.

Quick Buy – Real-world Evidence (RWE) Solutions Market Research Report: https://www.meticulousresearch.com/Checkout/51767128?utm_source=pr&utm_medium=social&utm_campaign=product&utm_content=08-12-2023

Based on end user, the pharmaceutical, biotechnology, & medical device companies’ segment is expected to witness the fastest growth rate during the forecast period. Rising pharmaceutical R&D spending is the major factor attributed to the growth of this segment. The cost of developing a new drug was more than $2,600 million in 2020 compared to $802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face. The global R&D spending in 2021 surged by 7.0% ($212 billion) compared to 2020. Real-world evidence helps in understanding real-life clinical practices and actual health outcomes of drugs. It also helps generate broader scientific evidence and commercial insights, valuable for the pharmaceutical industry.

Geographically, North America is expected to command the largest share of the RWE solutions market in 2022. The large market share of this region is mainly attributed to the increasing prevalence of chronic diseases, stringent regulations for drug approvals, implementation of the 21st Century Cures Act, availability of electronic datasets, advancements in the healthcare industry, and rising big data in healthcare sectors. The adoption of EHRs in the hospitals and patient registries is boosting the RWE solutions market in North America. The basic EHR adoption had increased since 2010 in the U.S. from 27.9% in 2010 to nearly 86% in 2017. As of 2022, 94% of the hospitals in the US are in the process of adopting EHRs.

This research report analyzes major geographies and provides comprehensive analysis for North America (U.S., Canada), Asia-Pacific (Japan, China, India, Australia, and RoAPAC), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Latin America, and the Middle East & Africa.

Key companies operating in the global RWE solutions market are IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Here are the top 10 companies operating in the Real-World Evidence Solutions Market @ https://meticulousblog.org/top-10-companies-in-real-world-evidence-solutions-market/?utm_source=pr&utm_medium=social&utm_campaign=product&utm_content=08-12-2023

Related Report:

Ø  RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post Market Surveillance), End User (Pharma, Payer, Provider) - Global Forecast to 2029

Here are the top 10 companies operating in the RWE Oncology Market  >>>  https://meticulousblog.org/top-10-companies-in-rwe-oncology-market/?utm_source=blog&utm_medium=social&utm_campaign=product&utm_content=08-12-2023

 

Ø  U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Forecast to 2029

Here are the top 10 companies operating in the U.S. Real-World Evidence (RWE) Solutions Market >> https://meticulousblog.org/top-10-companies-in-u-s-real-world-evidence-solutions-market/?utm_source=blog&utm_medium=social&utm_campaign=product&utm_content=08-12-2023

RWE Oncology Market: Use of real-world evidence for oncology clinical decision ...

 

According to a new market research report titled, ‘RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post-market Surveillance), and End User (Pharma, Payer) - Global Forecast to 2029,’ published by Meticulous Research^®, the real-world evidence oncology solutions market is expected to grow at a CAGR of 14.2% from 2022–2029 to reach $1.65 billion by 2029.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5276?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-11-2023

Real-world evidence (RWE) is clinical evidence gathered via RWD analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications in oncology, including drug development life cycles, reducing development duration, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. The growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare.

The RWE oncology market is segmented based on component (real-world datasets and RWE consulting & analytics services), application (drug development & approvals, market access & reimbursement/coverage decisions, post-market surveillance, medical device development & approvals, and other applications), end user (pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users), and geography (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa). The study also evaluates industry competitors and analyses the market at the regional and country levels.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5276?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-11-2023

Based on component, in 2022, the real-world datasets segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the growing amount of medical data generated in hospitals, increasing dependence on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers. In addition, the growing need for evidence generated from real-world data and a shift from volume to value-based care has resulted in an increased focus on cancer registries, a rise in the adoption of EHR/EMR in hospitals, and exponential growth in mobile health data and social media, leading to the generation of huge amounts of medical data.

Based on application, in 2022, the drug development & approvals segment is estimated to account for the largest share of the RWE oncology solutions market. Quality-of-life metrics and Patient-Reported Outcome Measures (PROMs) are becoming common elements in clinical trials for drug development. The evidence generated from real-world data is regularly utilized to inform aspects of drug development, such as the natural history and epidemiology of a disease and provide data on treatment pathways and comparator interventions in clinical practice. The rising number of cancer cases has compelled pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, which is expected to drive the growth of this segment.

Quick Buy – “RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post Market Surveillance), End User (Pharma, Payer, Provider) - Global Forecast to 2029” Research Report: https://www.meticulousresearch.com/Checkout/50669121?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-11-2023

Based on end user, in 2022, the pharmaceutical & medical device companies’ segment is estimated to account for the largest share of the RWE oncology solutions market. The large share of this segment is attributed to the increasing importance of RWE studies in cancer drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings. The healthcare landscape continues to shift from volume to value-based care and is continuously developing. Pharmaceutical companies are focusing on new ways to provide the best treatments for cancer patients. Real-world evidence enables health care professionals and pharmaceutical companies to understand real-life clinical practices and actual health outcomes of drugs. Thus, pharmaceutical and biotech companies are increasingly utilizing real-world evidence to collect real-time post-trial information about drugs, enabling healthcare providers and researchers to understand the negative reactions, side effects, and medication errors related to the drugs, thereby allowing them to control the potential harm caused by the drugs.

Based on Geography, in 2022, North America is estimated to account for the largest share of the RWE oncology market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The high market growth in North America is attributed to the increasing number of cancer cases, stringent regulations for drug approvals, implementation of the 21st Century Cures Act, increased usage of electronic datasets, advanced healthcare industry, and the rising amount of big data in healthcare.

The key companies operating in the RWE oncology market are IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

TOP 10 COMPANIES IN REAL-WORLD EVIDENCE (RWE) SOLUTIONS MARKET https://meticulousblog.org/top-10-companies-in-real-world-evidence-solutions-market/?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-11-2023

Scope of the Report:

RWE Oncology Solutions Market, by Component

• Real-world Datasets
• Disparate Datasets
• EMR/EHR/Clinical Data
• Claims & Billing Data
• Pharmacy Data
• Cancer Registries
• Other Disparate Datasets
• Integrated Datasets
• Real-world Consulting & Analytics Services
  (Note: Other Disparate Datasets include data generated from mobile applications, wearable devices, and social media).

RWE Oncology Solutions Market, by Application

• Drug Development & Approvals
• Market Access & Reimbursement/Coverage Decisions
• Post-market Surveillance
• Medical Device Development & Approvals
• Other Applications

            (Note: Other Applications include regulatory and clinical decision-making).

RWE Oncology Solutions Market, by End User

• Pharmaceutical, Biotechnology, and Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Other End Users

            (Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies).

Conti ...

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5276?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-11-2023

Related Reports:

·         Real-world Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Global Forecast to 2029  >> https://www.meticulousresearch.com/product/real-world-evidence-solutions-market-4954?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-11-2023

 

·         U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Forecast to 2029 >> https://www.meticulousresearch.com/download-sample-report/cp_id=5243

 

U.S. Real-World Evidence (RWE) Solutions Market Worth $2.22 billion by 2029

 

Meticulous Research^®– leading U.S. market research company published a research report titled “U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers)- Forecast to 2029.”

According to this latest publication from Meticulous Research®, the U.S. real-world evidence (RWE) solutions market is expected to grow at a CAGR of 13.1% from 2022 to 2029 to reach $2.22 billion by 2029. Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare have been considered to positively impact the U.S. RWE solutions market. However, one of the biggest challenges in the market is the lack of standard principles for the design, conduct, analysis, and reporting of RWE. This lack of consensus may affect the quality of the clinical trial studies to determine the comparative effectiveness of different treatment options.

Download Sample Research Paper @ https://www.meticulousresearch.com/download-sample-report/cp_id=5243?utm_source=blog&utm_medium=social&utm_campaign=product&utm_content=26-10-2023

The U.S.RWE solutions market study presents historical market data in terms of values (2020 and 2021), estimated current data (2022), and forecasts it for 2029–by Component (Datasets and Consulting Services), Application (Market Access & Reimbursement/Coverage Decisions, Drug Development & Approvals, Post Market Surveillance, Medical Device Development & Approvals, and Clinical and Regulatory Decision-making), and End User (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, and Other End Users).

Based on component, the datasets segment is expected to account for the largest share of the U.S.RWE solutions market in 2022. The large share of this segment is primarily attributed to the increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment; the growing amount of medical data generated in hospitals; increasing dependence of outcome-based studies on real-world data; and rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Download Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5243?utm_source=blog&utm_medium=social&utm_campaign=product&utm_content=26-10-2023

 

Based on application, the market access & reimbursement/coverage decisions segment is expected to account for the largest share of the U.S. RWE solutions market in 2022. The large share of this segment is primarily attributed to the increasing demand for real-world data and real-world evidence to accelerate drug discovery and development, increasing investments by biopharmaceutical companies in R&D, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE). Both industry and payers are increasingly considering real-world data (RWD) in the U.S. Payers use the data to support coverage decisions, develop guidelines and decision support tools for use in clinical practice, generate estimates of the potential population they cover that could require the treatment, and estimate potential costs and cost offsets.

Based on end user, the pharmaceutical & medical device companies segment is expected to account for the largest share of the U.S. RWE solutions market in 2022. The large share of this segment is mainly attributed increasing importance of RWE studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings. The healthcare landscape continues to shift from volume to value-based care and is continuously developing. Pharmaceutical companies have been looking for new ways to provide the best treatments for patients. Real-world evidence helps understand real-life clinical practices and actual health outcomes of drugs. Pharmaceutical and biotech companies are increasingly utilizing real-world evidence for collecting real-time post-trial information about drugs, which helps healthcare providers and researchers understand the negative reactions, side effects, and medication errors related to the drugs, thereby enabling them to control the potential harm caused by the drugs.

Key companies operating in the U.S.RWE solutions market are Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA HOLDINGS INC. (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).

TOP 10 COMPANIES IN U.S. REAL WORLD EVIDENCE SOLUTIONS MARKET @ https://meticulousblog.org/top-10-companies-in-u-s-real-world-evidence-solutions-market/?utm_source=blog&utm_medium=social&utm_campaign=product&utm_content=26-10-2023

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

Real-world Evidence (RWE) Solutions Market Worth $4.9 Billion by 2029

 

According to a new market research report titled, “Real-World Evidence Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Forecast to 2029”, published by Meticulous Research^®, the RWE solutions market is expected to grow at a CAGR of 11.8% from 2022–2029 to reach $4.9 billion by 2029.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=4954?utm_source=pr&utm_medium=social&utm_campaign=product&utm_content=28-08-2023

Real-world evidence (RWE) is clinical evidence gathered via RWD analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications, including drug development life cycles, shortening development timelines, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. The growth of this market is driven by key factors such as the rapid growth of large data in healthcare, the shift from volume to value-based care, and the rising focus towards personalized healthcare.

Impact of COVID-19 on RWE Solutions Market

The key players operating in the RWE solutions market experienced an initial market shrinkage due to uncertainties associated with the impact of the COVID-19 pandemic. The market shrinkage was mainly due to significant restrictions on travel in many countries, shifting of resources on COVID-19 treatments in healthcare settings, and limited access to hospitals. These factors affected the amount of real-world data generated globally.

However, after the initial shrinkage, real-world evidence (RWE) is set to become the most influential emerging technology to fight against the COVID-19 outbreak. Real-world evidence solutions can provide valuable insights to better understand, monitor, and prepare for the challenges caused by the COVID-19 pandemic. RWD has been used increasingly to map the progression of the disease and to discover vaccines and immediate treatments. Thus, the effectiveness of the use of RWD made a significant impact during the pandemic and continues to play a significant role in the treatment of infected patients.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business:  https://www.meticulousresearch.com/speak-to-analyst/cp_id=4954

RWE Solutions Market: Future Outlook

The RWE solutions market is segmented by component (datasets and consulting services), application (market access & reimbursement/coverage decisions, drug development & approvals, post market surveillance, medical device development & approvals, and other applications), end user (pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users) and Geography (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa). The study also evaluates industry competitors and analyzes their market shares at the global and regional levels.

Based on component, the datasets segment is estimated to account for the largest share of the RWE solutions market in 2022. The large market share of this segment is attributed to the increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, increasing dependence of outcome-based studies on real-world data, and rising demand for information regarding drug safety among payers, regulatory bodies, and providers. However, the consulting services segment is expected to witness the fastest growth rate during the forecast period. Real-world evidence consulting service providers make use of robust real-world datasets generated by conducting prospective/observational studies to offer customized consulting services to generate fit-for-purpose data and insights for their stakeholders instead of providing terabytes of data.

Based on application, the market access & reimbursement/coverage decisions segment is estimated to account for the largest share of the RWE solutions market in 2022. However, the drug development & approvals segment is expected to witness the fastest growth rate during the forecast period. Factors attributing to the growth of this segment include increasing demand for real-world data and real-world evidence to accelerate drug discovery and development and increasing investments by biopharmaceutical companies in R&D. In the field of drug development, quality-of-life metrics and Patient-reported Outcome Measures (PROMs) are now becoming common elements in clinical trials. The evidence generated from real-world data is regularly utilized to inform aspects of drug development. The role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs.

Quick Buy – Real-world Evidence (RWE) Solutions Market Research Report: https://www.meticulousresearch.com/Checkout/51767128?utm_source=pr&utm_medium=social&utm_campaign=product&utm_content=28-08-2023

Based on end user, the pharmaceutical, biotechnology, & medical device companies’ segment is expected to witness the fastest growth rate during the forecast period. Rising pharmaceutical R&D spending is the major factor attributed to the growth of this segment. The cost of developing a new drug was more than $2,600 million in 2020 compared to $802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face. The global R&D spending in 2021 surged by 7.0% ($212 billion) compared to 2020. Real-world evidence helps in understanding real-life clinical practices and actual health outcomes of drugs. It also helps generate broader scientific evidence and commercial insights, valuable for the pharmaceutical industry.

Geographically, North America is expected to command the largest share of the RWE solutions market in 2022. The large market share of this region is mainly attributed to the increasing prevalence of chronic diseases, stringent regulations for drug approvals, implementation of the 21st Century Cures Act, availability of electronic datasets, advancements in the healthcare industry, and rising big data in healthcare sectors. The adoption of EHRs in the hospitals and patient registries is boosting the RWE solutions market in North America. The basic EHR adoption had increased since 2010 in the U.S. from 27.9% in 2010 to nearly 86% in 2017. As of 2022, 94% of the hospitals in the US are in the process of adopting EHRs.

This research report analyzes major geographies and provides comprehensive analysis for North America (U.S., Canada), Asia-Pacific (Japan, China, India, Australia, and RoAPAC), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Latin America, and the Middle East & Africa.

Key companies operating in the global RWE solutions market are IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Here are the top 10 companies operating in the Real-World Evidence Solutions Market @ https://meticulousblog.org/top-10-companies-in-real-world-evidence-solutions-market/?utm_source=pr&utm_medium=social&utm_campaign=product&utm_content=28-08-2023